Dasatinib

製品コードS1021 別名:BMS-354825

Dasatinib化学構造

分子量(MW):488.01

Dasatinibは一種の新たで、有効な多ターゲット阻害剤で、無細胞試験でAbl、Srcとc-Kitに作用する時のIC50値が1 nM以下、0.8 nMと79 nMにそれぞれ分かれることです。

サイズ 価格(税別) 在庫  
JPY 23240.00 あり
JPY 24402.00 あり
JPY 61420.00 あり

文献中の使用例(63)

カスタマーフィードバック(11)

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

製品安全説明書

Src阻害剤の選択性比較

生物活性

製品説明 Dasatinibは一種の新たで、有効な多ターゲット阻害剤で、無細胞試験でAbl、Srcとc-Kitに作用する時のIC50値が1 nM以下、0.8 nMと79 nMにそれぞれ分かれることです。
ターゲット
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外試験

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NVrrbI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NkBp M3XzVWROW09? MYDJR|UxRTBwMECwNFch|ryP MlrvNVc6PTZyOEC=
K562 NF7E[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC4O|IhcA>? MWrEUXNQ NWiwTHhkUUN3ME2wMlAxOSEQvF2= NGHkU3EyPzl3NkC4NC=>
M07e NGXJfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H4ZVczKGh? NULGeIdTTE2VTx?= MXLJR|UxRTBwMECxNkDPxE1? M3zYblE4QTV4MEiw
ALL3 NGDj[GVEgXSxdH;4bYMhSXO|YYm= NFHS[2sxNjIQvF2= MonpO|IhcA>? MkXQSG1UVw>? MW\JR|UxRTBwMECwOEDPxE1? NUXlcpNWOTl6OEm1OFA>
CML MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfqNlAhdWmw MUjEUXNQ NWDlXnFvUUN3ME2wMlAxOSEQvF2= MlvxNVkzOTlyMU[=
BA/F3 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonFO|IhcA>? MYnEUXNQ NVH5foVKUUN3ME22MlU5QSEQvF2= MlfvNlMxQDh4NES=
BA/F3 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\uO|IhcA>? NFfxSHBFVVOR MnOwTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= NEPOW3UzOzB6OE[0OC=>
BA/F3 M2PTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\leZM4OiCq NEmzfpdFVVOR NY\SVG9lUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= MmPDNlMxQDh4NES=
BA/F3 NY\GXY9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e0blczKGh? MYfEUXNQ MWjJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? Ml\aNlMxQDh4NES=
BA/F3 M37HNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe4O|IhcA>? M3nWNWROW09? MWnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? NFzpcWozOzNyMUewNy=>
BA/F3 M3nZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NkBp M1rWS2ROW09? M3z5dGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP M3zacVI{OzBzN{Cz
BA/F3 M2jQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfwfHQ4OiCq NFHBemdFVVOR MYfJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? NWTDSFF4OjN|MEG3NFM>
BA/F3 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[3NkBp MU\EUXNQ M1rCSmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1? Mn3FNlM{ODF5MEO=
BA/F3 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrVc2hXPzJiaB?= MmXESG1UVw>? M1nZRWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP M{fVUVI{OzBzN{Cz
BA/F3 NU[5PI1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjwO|IhcA>? MVrEUXNQ M3XmZmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO MnnCNlM{ODF5MEO=
BA/F3 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTvbYlbPzJiaB?= NHnUfZlFVVOR NF\4RpBKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?= Mlr1NlM{ODF5MEO=
BA/F3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj0Z4s4OiCq M4juR2ROW09? NIrVZohKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? MXSyN|MxOTdyMx?=
BA/F3 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\lN5g1PzJiaB?= MoLRSG1UVw>? MV\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? MWeyN|MxOTdyMx?=
T cell MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDpO|IhcA>? M13SPGROW09? MVjJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> NV65WnF2OTdzNUS1NVI>
WiDr MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInh[HY4OiCq NX\qR3hGTE2VTx?= Ml;UTWM2OD1yLkC1NkDPxE1? NGj3cFAyPTZzNUWxNi=>
PC3 NFnFR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjmO|IhcA>? Mn\QSG1UVw>? NXT3d3hyUUN3ME2wMlAxQTRizszN NH3HXmkyPTZzNUWxNi=>
MDA-MB-231 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfEO|IhcA>? NVf5UVRZTE2VTx?= NFPi[5JKSzVyPUCuNFEzKM7:TR?= NX3jXZgyOTV4MUW1NVI>
Hs578T NYP2VVE3S3m2b4TvfIlkKEG|c3H5 MmrXO|IhcA>? M3TDfGROW09? M3rleWdKPTB;MD6wN{DPxE1? M1nUNFI1ODF3M{K3
HMEC M4TTZmN6fG:2b4jpZ{BCe3OjeR?= NH3yTJI4OiCq NUfJZ257TE2VTx?= MWrHTVUxRTFwODFOwG0> MoHkNlQxOTV|Mke=
DU145 M4eyRWN6fG:2b4jpZ{BCe3OjeR?= MkHTO|IhcA>? MXXEUXNQ NWnhPXJDT0l3ME2wMlE3KM7:TR?= MlnsNlQxOTV|Mke=
U251 MXPDfZRwfG:6aXOgRZN{[Xl? MYm3NkBp MVHEUXNQ M{TBeGdKPTB;Mj64NUDPxE1? NUjKbG9OOjRyMUWzNlc>
NCI60 MVzDfZRwfG:6aXOgRZN{[Xl? NWfuSoxFPzJiaB?= NI\zZZZFVVOR MUfHTVUxRTVwNzFOwG0> NWfMcmFTOjRyMUWzNlc>
MALME-3M M4DjV2N6fG:2b4jpZ{BCe3OjeR?= M33ldVczKGh? MoXFSG1UVw>? NUiyPFkxT0l3ME22MlYyKM7:TR?= MWSyOFAyPTN{Nx?=
KM12 MV\DfZRwfG:6aXOgRZN{[Xl? M1v4[VczKGh? MkC0SG1UVw>? NEjWTpBIUTVyPUeuOFQh|ryP Mm[yNlQxOTV|Mke=
SW620 MYTDfZRwfG:6aXOgRZN{[Xl? M3i4NlczKGh? MVTEUXNQ M1m5bmdKPTB;OD60N{DPxE1? MXmyOFAyPTN{Nx?=
RXF 393NL NUCxU4VrS3m2b4TvfIlkKEG|c3H5 NHG5XIo1KGSjeYO= M2CzcmROW09? Mn\ITWM2OD1yLkCyNVch|ryP NFfOXJIzOzJ3M{C3OC=>
LXFA 983L M1zwTGN6fG:2b4jpZ{BCe3OjeR?= M3P3TFQh\GG7cx?= M{jpd2ROW09? MnL6TWM2OD1yLkC1OlUh|ryP NYjPTppROjN{NUOwO|Q>
PRXF DU145 MVTDfZRwfG:6aXOgRZN{[Xl? NVrFNIZtPCCmYYnz NEfJVVZFVVOR M2G1b2lEPTB;MD6wOlI{KM7:TR?= MYWyN|I2OzB5NB?=
PAXF 1657L NYjRclJmS3m2b4TvfIlkKEG|c3H5 NFrnSWg1KGSjeYO= NHv6ZW1FVVOR NW\OT2prUUN3ME2wMlEzOSEQvF2= MkmxNlMzPTNyN{S=
CXF 1103L M3L2WGN6fG:2b4jpZ{BCe3OjeR?= NUO0V2NWPCCmYYnz NIfPfFFFVVOR NESwSHVKSzVyPUSuN|Yh|ryP NITz[YwzOzJ3M{C3OC=>
GXF251L MYfDfZRwfG:6aXOgRZN{[Xl? MXG0JIRigXN? MWXEUXNQ MYDJR|UxRTJwMkWg{txO NYftZYFuOjN{NUOwO|Q>
NCI-H23 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP4dYVwPzJiaB?= MUPEUXNQ NFjITW9KSzVyPUKuNlch|ryP Mo[wNlM2OjFyMkC=
HCT116 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi3NkBp NVfSS5hYTE2VTx?= NVXVNHVFUUN3ME2yMlMh|ryP MY[yN|UzOTB{MB?=
MCF7 M1LHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TJXVczKGh? MXLEUXNQ MX7JR|UxRTJwNUeg{txO M1fFPFI{PTJzMEKw
NCI-H460 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln6O|IhcA>? NVSwNZk3TE2VTx?= MnnPTWM2OD16Lkm5JO69VQ>? MUWyN|UzOTB{MB?=
DLD1 NHTQfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn3bm9ZPzJiaB?= NHrWXFZFVVOR M1Xxd2lEPTB;ND62JO69VQ>? NWPzRXI1OjN3Nke5OlA>
NCI-H661 NVjLeYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXi3NkBp MW\EUXNQ NYXpUXJ2UUN3ME23Mlgh|ryP MnnsNlM2Pjd7NkC=
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz4c|FNPzJiaB?= M2rxfWROW09? MYLJR|UxRThwMjFOwG0> M{PZ[FI{PTZ5OU[w
U937 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHIeHRqPzJiaB?= NVjlWottTE2VTx?= NVi0V2xIUUN3ME2xNk4zKM7:TR?= NHK2RVIzOzV4N{m2NC=>
HEK293 NXzabYxxTnWwY4Tpc44hSXO|YYm= MWqxNOKh|ryP M1fBOGROW09? MYLJcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= NELZbpIzOjd5ME[xNC=>
HUVEC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jnOlAvOTYEoN88US=> NUXBbY1{PzJiaB?= NF7xZmJFVVOR M4e3Umlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> NVfYepNHOjJ6NUO5PVM>
HUVEC NFL0VlNHfW6ldHnvckBCe3OjeR?= NYnJV|FQOTYEoN88US=> NIPBNos4OiCq M4rScWROW09? M{jPOmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO NVnKdGhpOjJ6NUO5PVM>
Plasmodium falciparum NEDm[VZHfW6ldHnvckBCe3OjeR?= MmLrNVDDqM7:TR?= MYSxOUBucW5? MmK1SG1UVw>? NGTtS2NKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? NXzY[4xXOjR3NUCzN|A>
PC3 NEDN[21HfW6ldHnvckBCe3OjeR?= MmXRNE4yKM7:TR?= MoLhOUBp NVflbnhmTE2VTx?= M13IUWlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MWqxPVQ3Ojl5NR?=
DU145 MoXiSpVv[3Srb36gRZN{[Xl? NID3VZUxNjFizszN NFLPS2k2KGh? NYnST5d{TE2VTx?= NWnMbmZiUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0> NE\l[noyQTR4Mkm3OS=>
PC3 NGr2S21McW6jc3WgRZN{[Xl? MmruNE4yKM7:TR?= M2fhWFUhcA>? NF\LO|NFVVOR NED3XFhKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N MV:xPVQ3Ojl5NR?=
DU145 MlToT4lv[XOnIFHzd4F6 M2LkeVAvOSEQvF2= NGG3ZYM2KGh? M37veGROW09? NGK3XnJKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> MoflNVk1PjJ7N{W=
PC3 NUnoN4d2U2mwYYPlJGF{e2G7 NFjVd3gxNjFizszN Moq0OUBp NIH3OY5FVVOR MmG5TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O MkfVNVk1PjJ7N{W=
DU145 MVTLbY5ie2ViQYPzZZk> NGrvfIoxNjFizszN M{ThUlUhcA>? NXTvVm4yTE2VTx?= NGH4V21KdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= NUTSZWxjOTl2NkK5O|U>
Huh7 M{PqPGFvfGm4aYLhcEBCe3OjeR?= NITBNpgzNjVizszN MWS0JIRigXN? NFXvfnFFVVOR NXKz[HZiUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN MnziNVc{PjB4N{[=
C6/36 MWLBcpRqfmm{YXygRZN{[Xl? MX2yMlUh|ryP MX:0JIRigXN? MnjtSG1UVw>? M{nGXGlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? Mnu4NVc{PjB4N{[=
U937 Mnn3SpVv[3Srb36gRZN{[Xl? M1XuRlEh|ryP NVzMOo1UOSCq M4GyVGROW09? NFTsdGxT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?= MnfDNVc3QDRyOUm=
U937 Mle5SpVv[3Srb36gRZN{[Xl? NV7lWWZnOSEQvF2= M1zJN|EhcA>? NWGzUmhFTE2VTx?= M3\yUHJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ MlTONVc3QDRyOUm=
murine mast cell MlfDSpVv[3Srb36gRZN{[Xl? M4nQflEh|ryP NGPMdnIzPCCq MUPEUXNQ NEC5[YxKdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?= MWWxO|Y5PDB7OR?=
BV-173 M{m4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33HSWlEPTB;MD6wNFAxODBzMEmg{txO Mmq2V2FPT0WU
K-562 M{jOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjQ[HdCUUN3ME2wMlAxODByMEK2OkDPxE1? NV\vSIg1W0GQR1XS
BL-70 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfxSHRKSzVyPUCuNFAxODByOEKyJO69VQ>? NVeweIVvW0GQR1XS
EM-2 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT0SGVuUUN3ME2wMlAxODByMUC4JO69VQ>? M2nIXXNCVkeHUh?=
LAMA-84 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fHN2lEPTB;MD6wNFAxODN{MTFOwG0> NXLlOW5pW0GQR1XS
MEG-01 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XZUmlEPTB;MD6wNFAxODl6IN88US=> NGS2PIxUSU6JRWK=
EoL-1-cell NF[1SZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;5VItTUUN3ME2wMlAxODBzM{Gg{txO MXHTRW5ITVJ?
CTV-1 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13mbGlEPTB;MD6wNFAxPDB2IN88US=> MofEV2FPT0WU
TE-15 NYXRNppjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrpbVBKSzVyPUCuNFA2QDlizszN NU[5OWd3W0GQR1XS
NOS-1 M1rMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLZ[|RCUUN3ME2wMlAxPjF|IN88US=> MmXtV2FPT0WU
D-336MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m1OmlEPTB;MD6wNFY{KM7:TR?= MXXTRW5ITVJ?
LB1047-RCC M3LTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rBeGlEPTB;MD6wNFk5QSEQvF2= NY\YdI5kW0GQR1XS
LB996-RCC M3PSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIqzeoxKSzVyPUCuNFA6QTFizszN NFXUSVFUSU6JRWK=
SW982 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PlWWlEPTB;MD6wNVEyPSEQvF2= NHfufppUSU6JRWK=
TK10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPuTWM2OD1yLkCxNVc1KM7:TR?= MoLCV2FPT0WU
A704 NFrJXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\tOXR[UUN3ME2wMlAyPDlzIN88US=> NX;mcZRlW0GQR1XS
TE-8 NF;YbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPwNoF2UUN3ME2wMlAyPTd4IN88US=> MnWwV2FPT0WU
DOHH-2 NEO3[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTrTWM2OD1yLkCxO|E6KM7:TR?= MlvaV2FPT0WU
HOP-62 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTMTWM2OD1yLkCxPFM1KM7:TR?= NHnBUWpUSU6JRWK=
TE-12 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G3eGlEPTB;MD6wNVg3OSEQvF2= MlP6V2FPT0WU
KGN Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMEG5OFIh|ryP NWnGN|ZwW0GQR1XS
NCI-H1648 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMEKwNVEh|ryP NHraUGlUSU6JRWK=
OS-RC-2 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\LTWM2OD1yLkCyNFMh|ryP MUHTRW5ITVJ?
GB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEKxOVch|ryP NF3ZcJFUSU6JRWK=
RXF393 NXzIfnFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q0ZWlEPTB;MD6wNlM2PyEQvF2= M4WwR3NCVkeHUh?=
LC-2-ad MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEK1PFYh|ryP M4H0enNCVkeHUh?=
KS-1 NFj0doZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K1fGlEPTB;MD6wNlc{KM7:TR?= MULTRW5ITVJ?
ETK-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPFV5V1UUN3ME2wMlAzQDN{IN88US=> M36wOnNCVkeHUh?=
SW954 M1frd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEK5Nlch|ryP NYjDdpRuW0GQR1XS
Becker NHzYdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnRTWM2OD1yLkCzNFA{KM7:TR?= M{TWPHNCVkeHUh?=
MZ1-PC NXGyPZBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjzdHVKSzVyPUCuNFMyOTlizszN NUXTXI8zW0GQR1XS
ES6 NFrIfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEOxPVMh|ryP MX7TRW5ITVJ?
KURAMOCHI MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMEO0PFch|ryP NYnKRnpYW0GQR1XS
CGTH-W-1 NEi0elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEO1OFgh|ryP M3zzSXNCVkeHUh?=
VA-ES-BJ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEO5NFIh|ryP MYHTRW5ITVJ?
LXF-289 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTLOFduUUN3ME2wMlA{QTV4IN88US=> MX7TRW5ITVJ?
MPP-89 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HrSWlEPTB;MD6wOFA1QSEQvF2= M{S5PHNCVkeHUh?=
SW872 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXNcWJKSzVyPUCuNFQyPjFizszN M1;CRnNCVkeHUh?=
SNB75 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13afWlEPTB;MD6wOFQ{PSEQvF2= MUPTRW5ITVJ?
PSN1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMES0O|Qh|ryP NUm0RYFNW0GQR1XS
LB831-BLC M4fvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPTR|VoUUN3ME2wMlA1PjB7IN88US=> NXnXU5psW0GQR1XS
MFH-ino M3fVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\pc3BzUUN3ME2wMlA1PzJ2IN88US=> Mn3OV2FPT0WU
TGBC24TKB MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TmVmlEPTB;MD6wOFc3OSEQvF2= NXfOOVBJW0GQR1XS
A388 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHycm1KSzVyPUCuNFUxQTVizszN NVrlZ4JHW0GQR1XS
BB30-HNC M4PqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KzeWlEPTB;MD6wOVQ{PyEQvF2= M1HDT3NCVkeHUh?=
GI-ME-N NHXhcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknlTWM2OD1yLkC2NVE5KM7:TR?= Mn\wV2FPT0WU
TGBC1TKB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnnenZMUUN3ME2wMlA3OTZ2IN88US=> NYjEXGc6W0GQR1XS
TE-10 NHzwOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XT[2lEPTB;MD6wOlM2PyEQvF2= NX;OW5NCW0GQR1XS
A498 MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEeyPFQh|ryP NV\oXYc4W0GQR1XS
TE-11 NIWwc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LKXGlEPTB;MD6wO|g2QCEQvF2= NHr2[mxUSU6JRWK=
BB65-RCC NHTpZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEiyNlch|ryP MX3TRW5ITVJ?
C2BBe1 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPZOYNZUUN3ME2wMlA5OzB6IN88US=> M4G2SnNCVkeHUh?=
NCI-H747 NYK2boVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvpTWM2OD1yLkC4N|YzKM7:TR?= NFn4OIFUSU6JRWK=
IST-MES1 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnYVoFUUUN3ME2wMlA5PTV{IN88US=> NYDu[3h7W0GQR1XS
KALS-1 NUD2e5d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHCPYpvUUN3ME2wMlA6PDlizszN MonxV2FPT0WU
GCIY MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTtemJZUUN3ME2wMlA6PjV4IN88US=> NV24Ooo3W0GQR1XS
RL95-2 NUj1bZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofRTWM2OD1yLkGwN|gh|ryP MlfPV2FPT0WU
TE-1 M3Phcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zqV2lEPTB;MD6xNFU1KM7:TR?= M2HtdXNCVkeHUh?=
NCI-H1355 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KwbGlEPTB;MD6xNVAzQCEQvF2= MorXV2FPT0WU
SW962 NXrUVoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj0b4JKSzVyPUCuNVEzQTJizszN NELtVIlUSU6JRWK=
KLE NYLvZ2hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnvV3VKSzVyPUCuNVE{OTdizszN NHf2[XNUSU6JRWK=
MC116 NXvLOG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTmb25KSzVyPUCuNVE1OSEQvF2= M37m[HNCVkeHUh?=
NMC-G1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMUG2NFYh|ryP MYjTRW5ITVJ?
KU812 M3W3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjz[FFVUUN3ME2wMlEyQDh|IN88US=> NWnEOWpsW0GQR1XS
COLO-829 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMUKyNVMh|ryP NG\Td3JUSU6JRWK=
NTERA-S-cl-D1 M33vb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMUKyPFMh|ryP MVrTRW5ITVJ?
IST-MEL1 NYjHeZhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;KS2lEPTB;MD6xN|Q2KM7:TR?= MYLTRW5ITVJ?
MLMA NX6yd5ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMUSwN|Ih|ryP NUfZNGpvW0GQR1XS
LS-123 M4[wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f4cGlEPTB;MD6xOFA3PCEQvF2= NHPjWGJUSU6JRWK=
LB2518-MEL NGPpUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\Ge2lEPTB;MD6xOFE3OiEQvF2= MoXqV2FPT0WU
NB69 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXVRo5EUUN3ME2wMlE1PDN4IN88US=> MUHTRW5ITVJ?
8-MG-BA NGTielZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO1TWM2OD1yLkG1OFU5KM7:TR?= NEDsSmVUSU6JRWK=
K5 NWfK[nh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELrb5hKSzVyPUCuNVY1QDlizszN MnfFV2FPT0WU
KINGS-1 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGwTWM2OD1yLkG2OlY3KM7:TR?= M3X5UXNCVkeHUh?=
SF268 NFHPRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMUe0NFQh|ryP NH;MOpRUSU6JRWK=
PF-382 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTRTWM2OD1yLkG3Olc5KM7:TR?= NVLXWHM5W0GQR1XS
SH-4 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnlTWM2OD1yLkG4OFE{KM7:TR?= M1XFe3NCVkeHUh?=
NALM-6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG2OYR{UUN3ME2wMlE6Ojl3IN88US=> MUPTRW5ITVJ?
CP66-MEL NVvsbldwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPlTWM2OD1yLkG5OVMyKM7:TR?= NYX4bW1EW0GQR1XS
697 NGHt[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XjemlEPTB;MD6xPVk5PyEQvF2= NXnuUY9ZW0GQR1XS
CP67-MEL Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTY[29KSzVyPUCuNlA1QDhizszN MWXTRW5ITVJ?
DSH1 NWjHXFdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ezXGlEPTB;MD6yOFAxOSEQvF2= NFfiblNUSU6JRWK=
HCE-4 NEj4UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XFPGlEPTB;MD6yOlQ{QSEQvF2= NU\MbZhkW0GQR1XS
MZ2-MEL NH7ufpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nsXWlEPTB;MD6yPFU{PyEQvF2= NGC0PW1USU6JRWK=
BL-41 Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfyTWM2OD1yLkK5NVI{KM7:TR?= MnvWV2FPT0WU
HUTU-80 NFfwNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y2S2lEPTB;MD6zNVQzKM7:TR?= NUjieFZ1W0GQR1XS
LOXIMVI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjUO5E4UUN3ME2wMlMyPTB|IN88US=> M1q3UXNCVkeHUh?=
no-10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3wXYZKSzVyPUCuN|E6OzFizszN MW\TRW5ITVJ?
KARPAS-422 NVfne4U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PFcmlEPTB;MD6zN|k6PyEQvF2= NF6wbmJUSU6JRWK=
SW684 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV22TZJGUUN3ME2wMlM1QThizszN MX7TRW5ITVJ?
SF126 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf4Znk5UUN3ME2wMlM2PDFizszN MnPzV2FPT0WU
D-263MG NV;rPIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jOSmlEPTB;MD6zOlIzPCEQvF2= NWj4WJpFW0GQR1XS
OVCAR-4 M1HVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDUNJVKSzVyPUCuN|c1OzNizszN MX;TRW5ITVJ?
BB49-HNC NFL1RmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDBfGhMUUN3ME2wMlM5PTl7IN88US=> NV3IXIpUW0GQR1XS
ONS-76 NEDkWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;MTWM2OD1yLkSyPVUyKM7:TR?= MYrTRW5ITVJ?
MZ7-mel MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwNEe5NVEh|ryP MnHUV2FPT0WU
RCC10RGB M2rYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jRdGlEPTB;MD60PVEyKM7:TR?= NX;hWYV2W0GQR1XS
BOKU NUfER2R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLNTWM2OD1yLkS5NVM{KM7:TR?= MWnTRW5ITVJ?
no-11 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfDOHRWUUN3ME2wMlUxOjJ6IN88US=> MYXTRW5ITVJ?
IST-SL2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n2c2lEPTB;MD61NFMxOiEQvF2= MV\TRW5ITVJ?
RKO Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17K[GlEPTB;MD61Nlk3PiEQvF2= Mo\EV2FPT0WU
HT-144 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:4eVJKSzVyPUCuOVM3ODlizszN M1\CfnNCVkeHUh?=
NCI-H446 NYXvboJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonVTWM2OD1yLk[yO|Yh|ryP MkHGV2FPT0WU
QIMR-WIL M3niZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3XTWM2OD1yLkewOlI6KM7:TR?= Ml:xV2FPT0WU
MHH-PREB-1 MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwN{S0Olkh|ryP M4PQbnNCVkeHUh?=
EW-16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzJVJFyUUN3ME2wMlc3OTd6IN88US=> MnTjV2FPT0WU
EW-24 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTBfolOUUN3ME2wMlc5OTZ3IN88US=> Mm\qV2FPT0WU
LB373-MEL-D MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnNVZd3UUN3ME2wMlgzPTB6IN88US=> MWrTRW5ITVJ?
TE-9 M1[wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnrTWM2OD1yLki3OVMzKM7:TR?= Mnn5V2FPT0WU
A3-KAW M1rnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwOUi0OVIh|ryP NWfYSWhkW0GQR1XS
A101D NULHdXJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zTc2lEPTB;MT6wN|A1OyEQvF2= M3;icHNCVkeHUh?=
OCUB-M M1PzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[zdWlEPTB;MT6wOFQyOiEQvF2= Ml;vV2FPT0WU
ES4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HrTmlEPTB;MT6wOVE1PSEQvF2= MnTnV2FPT0WU
TE-6 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXCTWM2OD1zLkKxNlI3KM7:TR?= NInIe3RUSU6JRWK=
D-502MG NHz6XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;kO5VyUUN3ME2xMlI{Ozd4IN88US=> NFPP[VlUSU6JRWK=
KNS-42 M1L4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrNUmFKSzVyPUGuNlQ1OTJizszN NVTUSlhpW0GQR1XS
SNU-C2B NWfuN3o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGweXU3UUN3ME2xMlMxPTh7IN88US=> M3rPb3NCVkeHUh?=
NCI-H1838 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LYTWlEPTB;MT6zNFc{OyEQvF2= NVzLW2VvW0GQR1XS
NKM-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwM{C4OVkh|ryP MWXTRW5ITVJ?
GI-1 NYfUSHU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHOVVRKSzVyPUGuN|YzOiEQvF2= MYXTRW5ITVJ?
NB5 NYLzV|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwM{m4Nlch|ryP MkPYV2FPT0WU
CAS-1 M1f3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fqbmlEPTB;MT60NFk6OiEQvF2= M37TUnNCVkeHUh?=
HCE-T NUO4eY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi1VI9KSzVyPUGuOVY4OTRizszN M1L1fHNCVkeHUh?=
SBC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHDcXRKSzVyPUGuOVc6QDRizszN M2jkV3NCVkeHUh?=
JiyoyeP-2003 NFfDOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwN{O0OlYh|ryP M4ToVnNCVkeHUh?=
TE-5 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO1UGgzUUN3ME2xMlc6OTN7IN88US=> Ml;jV2FPT0WU
CAN NIKxb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P1T2lEPTB;MT64NlI2OiEQvF2= M{f5NnNCVkeHUh?=
SK-UT-1 NI[1WpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L5OWlEPTB;Mj6xOlY6OyEQvF2= M{LafHNCVkeHUh?=
JVM-2 NGTjXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrsTWM2OD1{LkO2Nlg1KM7:TR?= MX\TRW5ITVJ?
LB771-HNC MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwNUe1OVEh|ryP M33NdnNCVkeHUh?=
NCCIT NWmyb|VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PvfmlEPTB;Mj64OlYyPiEQvF2= NWPve49pW0GQR1XS
NCI-H2126 NVzKU3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXVU5pKSzVyPUKuPFc2PTJizszN NFKyXXhUSU6JRWK=
Calu-6 NVvOXlM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwMEW3OFEh|ryP NHeyeZZUSU6JRWK=
SK-LMS-1 NWnMZWpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\aTWM2OD1|LkGxPFg3KM7:TR?= NWrDNo9xW0GQR1XS
ARH-77 NIHNN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPyNpBYUUN3ME2zMlQ3QTF3IN88US=> NYmzPZNSW0GQR1XS
NB17 NX7EdIYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHDTWM2OD1|Lk[zPFQ4KM7:TR?= NVO2Z2txW0GQR1XS
A253 NETJd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O4RWlEPTB;Mz63N|I1PiEQvF2= NGTHc3NUSU6JRWK=
OPM-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT0bYtjUUN3ME20MlI4Pjh3IN88US=> MkTQV2FPT0WU
MV-4-11 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rMdGlEPTB;ND6zOlQ2PCEQvF2= NUPqWVdYW0GQR1XS
SR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnoWW91UUN3ME20MlQ6QTV2IN88US=> M2S4S3NCVkeHUh?=
KG-1 M2joOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTDTWM2OD12Lk[wPFQ2KM7:TR?= MmP4V2FPT0WU
OCI-AML2 NGPCPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3VcG9DUUN3ME21Mlg3OTV2IN88US=> NIm3WpRUSU6JRWK=
D-247MG M3PL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZwMUK1NVkh|ryP MV3TRW5ITVJ?
DJM-1 NYLCbnhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvKTIFKSzVyPU[uOFg2PThizszN NF;wfJlUSU6JRWK=
RPMI-6666 NEjzOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjRTWM2OD15LkK3NFY4KM7:TR?= MoPFV2FPT0WU
KARPAS-45 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTdwNUG2O|Eh|ryP NVrFdYlmW0GQR1XS
LP-1 M{HjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS1dmFMUUN3ME23MlU1Pzh{IN88US=> NGGwbFlUSU6JRWK=
RS4-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLCUpNHUUN3ME23MlY2Pzh5IN88US=> MX3TRW5ITVJ?
DU-4475 NFO3N4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPB[GZKSzVyPUiuNlE3PTJizszN NIDZTWNUSU6JRWK=
MONO-MAC-6 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TkW2lEPTB;OD6yO|A3PiEQvF2= M33sTnNCVkeHUh?=
NCI-SNU-16 NY\lTXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrTTWM2OD16LkW2NVI5KM7:TR?= NWWxUphDW0GQR1XS
SJSA-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnZfWV6UUN3ME24MlczQDB3IN88US=> NVXzO5dlW0GQR1XS
MMAC-SF M2q1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnJPGlYUUN3ME24Mlc6OzB5IN88US=> MXPTRW5ITVJ?
SK-NEP-1 M3TiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonTTWM2OD16Lki5NVU2KM7:TR?= Mlm5V2FPT0WU
J-RT3-T3-5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRThwOU[1Nlkh|ryP NF\DdFhUSU6JRWK=
SKM-1 NEj3PYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPiOHRKSzVyPUmuNFE4OzRizszN M4nBU3NCVkeHUh?=
LB2241-RCC NILxZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TlPGlEPTB;OT6wNlAyOiEQvF2= MlTKV2FPT0WU
SIG-M5 M2r2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTlwMEK0PVMh|ryP MoDFV2FPT0WU
EVSA-T NHP3foFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULUNG1YUUN3ME25MlI4Pzl|IN88US=> MW\TRW5ITVJ?
GT3TKB NV\scI46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUniOXZiUUN3ME25MlM2PTR4IN88US=> NFHjOGpUSU6JRWK=
NB6 NUTZOVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrUXplyUUN3ME25MlkzOjV7IN88US=> M1fCWnNCVkeHUh?=
EHEB M2DDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvsT3lKSzVyPUGwMlA3PTZizszN MnroV2FPT0WU
HEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLmUmxKSzVyPUGwMlQ4PzZizszN MmDsV2FPT0WU
ALL-PO NYjiV|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFyLke5N|gh|ryP MX3TRW5ITVJ?
TGW MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nzUmlEPTB;MUGuNlgzQCEQvF2= NWX1V3lzW0GQR1XS
BC-3 NVTQ[mp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWThfY5zUUN3ME2xNk4yOTN6IN88US=> MVvTRW5ITVJ?
IA-LM MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XmSGlEPTB;MUKuOFQ1PSEQvF2= M4qwcnNCVkeHUh?=
UACC-257 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G3d2lEPTB;MUKuPVE6QCEQvF2= MoLlV2FPT0WU
KP-N-YS MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj0TWM2OD1zMj65Nlg{KM7:TR?= NX74XYRNW0GQR1XS
Raji M{LOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF|Lke0PVch|ryP Mn\iV2FPT0WU
SF539 NEDvVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF|Lki1OVch|ryP NFS1[pBUSU6JRWK=
DMS-153 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TnOGlEPTB;MUSuNFAzQCEQvF2= MUjTRW5ITVJ?
L-540 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDwdZdKSzVyPUG1MlA3PzJizszN M2W2XXNCVkeHUh?=
MN-60 M3jKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\mN3ROUUN3ME2xOU4yQTd7IN88US=> NXGyU2I3W0GQR1XS
RPMI-8866 NGTzZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF5LkS0OVQh|ryP NGHxfFhUSU6JRWK=
NCI-H510A NHPu[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF7LkO5O|Mh|ryP MmDwV2FPT0WU
NB13 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TGPWlEPTB;MUmuOFg4PyEQvF2= MYnTRW5ITVJ?
HAL-01 NFXVfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqzdWVsUUN3ME2xPU44PTR|IN88US=> MlPTV2FPT0WU
NCI-H720 NUXW[mJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\WXHhxUUN3ME2yNE4zPzN|IN88US=> MkD6V2FPT0WU
REH M4\XUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJyLk[zOVch|ryP MoK1V2FPT0WU
KNS-81-FD NIXZbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPTdYdZUUN3ME2yN{4yPDZizszN Mne1V2FPT0WU
HC-1 NH[wbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTiW5hlUUN3ME2yOE42PTVzIN88US=> MX;TRW5ITVJ?
NCI-H2141 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\CUZpwUUN3ME2yOE44PzV2IN88US=> MU\TRW5ITVJ?
MOLT-4 NFzNOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3VT5RKSzVyPUK2MlY4PTNizszN M{HNVnNCVkeHUh?=
OMC-1 M3vLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP0UpdCUUN3ME2yO{4yPDJ{IN88US=> MULTRW5ITVJ?
LC-1F MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3naRmlEPTB;MkeuN|I1PSEQvF2= NGX3eoRUSU6JRWK=
NCI-H1304 NHroZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mfXpKSzVyPUK4MlE3OjhizszN MWrTRW5ITVJ?
BC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\wTpdIUUN3ME2yPE43PTFizszN M2XqU3NCVkeHUh?=
NCI-H64 M2\lcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jDPGlEPTB;MkmuOlI2OyEQvF2= MXjTRW5ITVJ?
MOLT-16 M4TTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7YSXhKSzVyPUK5MlYzQTJizszN MXzTRW5ITVJ?
U-87-MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\Gb2lEPTB;M{CuO|Y3KM7:TR?= NYfnXXgyW0GQR1XS
GAK M13n[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjDeGxKSzVyPUOxMlI3QDZizszN MnfiV2FPT0WU
ES8 NFHWbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TBNGlEPTB;M{KuNVI2OiEQvF2= M4LkSHNCVkeHUh?=
HCC1599 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTN{LkOzNlUh|ryP NVGycHBOW0GQR1XS
EB-3 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPlV4hKSzVyPUO0MlMyOTdizszN M33yVXNCVkeHUh?=
HCC1187 M3nqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXRbYpKSzVyPUO1MlgxPTJizszN NFzmfFFUSU6JRWK=
SK-PN-DW Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfMNYhKSzVyPUO2MlE6PDNizszN M1nEbHNCVkeHUh?=
JVM-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN5LkKzN|gh|ryP MULTRW5ITVJ?
HCC2157 NYDDN3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPnOGU4UUN3ME2zO{46QTR4IN88US=> NILJU4dUSU6JRWK=
A4-Fuk NGjJe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\Yb2lEPTB;M{iuNVAxQSEQvF2= M1PUSnNCVkeHUh?=
COR-L279 M4XaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzVeohKSzVyPUSwMlI5PTFizszN NWThe2d2W0GQR1XS
DEL NH;uSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRzLkmwPFYh|ryP MmnMV2FPT0WU
NCI-H1395 M3rGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDOWHd2UUN3ME20Nk4xOTZ|IN88US=> NY\CSIpYW0GQR1XS
MHH-NB-11 NGq1OJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTR|LkC4NVgh|ryP NID2fmdUSU6JRWK=
NCI-H2107 MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT5TWM2OD12Mz60PFQ3KM7:TR?= M4G5XHNCVkeHUh?=
NEC8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTR2LkOzOkDPxE1? MkHBV2FPT0WU
COLO-684 NVHuRoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\xXGlEPTB;NE[uNlI2QCEQvF2= MYrTRW5ITVJ?
LS-411N M2H3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WyNmlEPTB;NEiuOFc1QCEQvF2= MXvTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
細胞試験:

[1]

+ 展開
  • 細胞株: Ba/F3 cell lines
  • 濃度: ~32 nM
  • 反応時間: 72 hours
  • 実験の流れ:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • 製剤: DMSO
  • 投薬量: 30 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管
別名 BMS-354825

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 問題2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src信号経路図

Src Inhibitors with Unique Features

相関Src製品

Tags: Dasatinibを買う | Dasatinib ic50 | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib化学構造 | Dasatinib分子量 | Dasatinib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID